Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Current Assets (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Current Assets for 8 consecutive years, with $149.0 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 143.14% to $149.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.0 million through Dec 2025, up 143.14% year-over-year, with the annual reading at $149.0 million for FY2025, 143.14% up from the prior year.
  • Current Assets for Q4 2025 was $149.0 million at Whitehawk Therapeutics, down from $165.0 million in the prior quarter.
  • The five-year high for Current Assets was $232.6 million in Q1 2025, with the low at $37.4 million in Q2 2021.
  • Average Current Assets over 5 years is $132.4 million, with a median of $140.3 million recorded in 2022.
  • The sharpest move saw Current Assets skyrocketed 232.49% in 2022, then plummeted 50.81% in 2024.
  • Over 5 years, Current Assets stood at $151.3 million in 2021, then grew by 19.01% to $180.0 million in 2022, then tumbled by 30.8% to $124.6 million in 2023, then tumbled by 50.81% to $61.3 million in 2024, then surged by 143.14% to $149.0 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $149.0 million, $165.0 million, and $178.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.